Anna Azvolinsky

Researchers at the Queen Mary U. of London and a team of collaborators have identified a genetic signature among prostate tumors that may facilitate determining appropriate course of treatment for patients. The results of the study will be published in the March 2011 issue of Lancet Oncology.

The FDA’s Oncologic Drugs Advisory Committee (ODAC) met last week to debate the value of the FDA's accelerated approval program for cancer drugs.